MedTrace Logo

Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus

NCT00290927 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2009-08-26

No results posted yet for this study

Summary

* To evaluate the superiority in the efficacy of HMR1964 and OHA combination therapy as compared with OHA therapy.
* To evaluate the superiority in the efficacy of HMR1964 mono-therapy as compared with OHA therapy.
* To evaluate the safety of HMR1964.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

insulin glulisine

Sponsors & Collaborators

Principal Investigators

  • Masayoshi KOYAMA · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290927 on ClinicalTrials.gov